MET and chordoma: Synergies observed with the ALK/MET-inhibitor crizotinib agree with existing data on both the target and the drug in chordoma and related diseases: several authors have reported expression of MET in a high proportion of clinical chordoma samples [39, 40] in the absence of recurrent MET mutations or amplifications [12].